Employers › Noven Pharmaceuticals
Recordkeeping fees per participant · Noven Pharmaceuticals, Inc. 401(k) Plan · plan year 2024
$46.23
Higher than 33% of the 5,847 plans $50 to 250M that report it.
= $24,781 / 536
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251009095208NAL0015185426001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009095208NAL0015185426001, received 2025-10-09
Percentiles compare this plan with the Schedule H plans $50 to 250M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-10-09.
Administrative expenses excluding investment management, per participant
$46.23
Higher than 23% of the 8,758 plans $50 to 250M that report it.
= $24,781 / 536
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251009095208NAL0015185426001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009095208NAL0015185426001, received 2025-10-09
Administrative expenses per participant
$139.52
Higher than 53% of the 9,042 plans $50 to 250M that report it.
= $74,781 / 536
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251009095208NAL0015185426001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009095208NAL0015185426001, received 2025-10-09
Administrative expenses as a share of assets
0.121%
Higher than 45% of the 9,049 plans $50 to 250M that report it.
= $74,781 / $61,855,786
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251009095208NAL0015185426001, received 2025-10-09
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251009095208NAL0015185426001, received 2025-10-09
Employer contributions per participant
$1,743
Higher than 26% of the 9,105 plans $50 to 250M that report it.
= $934,234 / 536
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251009095208NAL0015185426001, received 2025-10-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009095208NAL0015185426001, received 2025-10-09
Employer share of total contributions
22.0%
Higher than 25% of the 9,112 plans $50 to 250M that report it.
= $934,234 / $4,240,983
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251009095208NAL0015185426001, received 2025-10-09
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251009095208NAL0015185426001, received 2025-10-09
Plan terms are described in Noven Pharmaceuticals, Inc.'s SEC filings: Form 10-K filed 2009-03-13. No term could be quoted from them with the required precision.
2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2R participant brokerage window · 2S pre-approved plan document · 2T default investment (QDIA) · 3D IRS pre-approved plan · 3H controlled-group sponsor · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20251009095208NAL0015185426001, received 2025-10-09
| Field | Value | Source |
|---|---|---|
| Plan sponsor | NOVEN PHARMACEUTICALS, INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Plan name | NOVEN PHARMACEUTICALS, INC. 401(K) PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Sponsor EIN / plan number | 59-2767632 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Sponsor location | MIAMI, FL | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Filing received | 2025-10-09 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Participants, beginning of year | 506 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Active participants | 336 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Participants, end of year | 536 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Participants with an account balance | 536 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Total assets, beginning of year | $55,133,574 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Total assets, end of year | $61,855,786 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Net assets, end of year | $61,849,477 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Total income | $11,754,957 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Net income | $6,731,432 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Employer contributions | $934,234 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Participant contributions | $2,622,429 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Other contributions (incl. rollovers) | $684,320 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Total contributions | $4,240,983 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Benefit payments | $4,948,744 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Total expenses (incl. benefit payments) | $5,023,525 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Total administrative expenses | $74,781 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Contract administrator fees | $0 | Schedule H, line 2i(2); CONTRACT_ADMIN_FEES_AMT pos 106; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Recordkeeping fees | $24,781 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| IQPA audit fees | $0 | Schedule H, line 2i(4); IQPA_AUDIT_FEES_AMT pos 161; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Investment advisory and management fees | $50,000 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Administrative expenses excluding investment management | $24,781 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Held in master trusts | $0 | Schedule H, line 1c(11) col (b); INT_MASTER_TR_EOY_AMT pos 53; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Held in common/collective trusts | $38,359,034 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Held in mutual funds | $22,399,326 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20251009095208NAL0015185426001, received 2025-10-09 |
| Independent auditor | BDO USA, P.C. | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20251009095208NAL0015185426001, received 2025-10-09 |
Position = column in the DOL layout for form year 2024. Filing 20251009095208NAL0015185426001, received 2025-10-09.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| NFP RETIREMENT INC | INVESTMENT ADVISOR | 27 Investment advisory (plan) | $52,855 | no |
| EMPOWER ANNUITY INSURANCE COMPANY Orecordkeeper | RECORDKEEPER | 64 Recordkeeping fees | $31,146 | yes |
| CHARLES SCHWAB & CO., INC | NONE | 26 Investment advisory (participants); 33 Securities brokerage; 50 Direct payment from the plan; 59 Shareholder servicing fees; 71 Securities brokerage commissions and fees | $1 | yes |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20251009095208NAL0015185426001, received 2025-10-09.
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $55,133,574 | $61,855,786 | 12.2% |
| Participants with a balance | 500 | 536 | 7.2% |
| Administrative expenses | $86,031 | $74,781 | -13.1% |
| Recordkeeping fees per participant | $47.08 | $46.23 | -1.8% |
| Employer contributions | $822,989 | $934,234 | 13.5% |
Prior filing 20241007134719NAL0015284545001, received 2024-10-07; the plan years are contiguous.
Sponsor name as filed: NOVEN PHARMACEUTICALS, INC.; SEC registrant: NOVEN PHARMACEUTICALS INC (CIK 815838, matched by EIN).